EYPTEyePoint, Inc.
Price
-74%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, nothing alarming, growth fading, the market undecided.
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E technology (Durasert E) for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU1, is an investigational sustained delivery treatment for vascular endothelial growth factor (VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI) with the Company's bioerodible Durasert E drug delivery technology.
In the company’s own words · 10-K filed Mar 5, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
EyePoint, Inc. (EYPT) reported revenue of $507K in Q2 2026 (quarter ended Jun 30, 2026), down 90% from the same quarter a year earlier. That came with net loss of $94M. For the full year FY2025, revenue was $31M (−28% year on year) and net income −$232M. Its largest product in Q1 2026 (quarter ended Mar 31, 2026) was Royalty at $141K, 62% of the disclosed total, well ahead of License And Collaboration Agreement at 38%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 10, 2026On September 10, 2026, EyePoint, Inc. posted an updated investor presentation on its website at www.eyepoint.bio.Other event · Form 8-K
- Aug 17, 2026On August 17, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing topline data for LUGANO, one of its pivotal Phase 3 clinical trials evaluating DURAVYU™ for wet age-related macular degeneration (wet AMD)Other event · Form 8-K
- Jul 30, 2026On July 30, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing it has completed enrollment in the pivotal Phase 3 clinical trials evaluating DURAVYU™ for the treatment of diabetic macular edema ("DME")Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q1 2026 · $229.0KThe company’s own SEC segment disclosure.
- Royalty$141.0K62%
- License And Collaboration Agreement$88.0K38%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.